Department of Urology, Peking University First Hospital, Beijing, China.
Institute of Urology, Peking University, Beijing, China.
J Med Genet. 2023 May;60(5):477-483. doi: 10.1136/jmg-2022-108633. Epub 2022 Sep 7.
Approximately 20%-40% of patients with von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary disease, exhibit large deletions (LDs). Few studies have focused on this population. Hence, we aimed to elucidate the genotype-phenotype correlations and clinical outcomes in VHL patients with LDs.
In this retrospective study, we included 119 patients with VHL disease from 50 unrelated families in whom LDs were detected using traditional and next-generation sequencing methods. Other germline mutations were confirmed by Sanger sequencing. Genotype-phenotype correlations and survival were analysed in different groups using Kaplan-Meier and Cox regression. We also evaluated therapeutic response to tyrosine kinase inhibitor (TKI) therapy.
The overall penetrance of patients aged <60 was 95.2%. Two VHL patients with LDs also carried and germline mutations. An earlier age of onset of retinal haemangioblastoma was observed in the next generation. Patients with exon 2 deletion of had an earlier onset age of renal cell carcinoma and pancreatic lesions. The risk of renal cell carcinoma was lower in VHL patients with LDs and a deletion. The group with earlier age of onset received poorer prognosis. Four of eight (50%) patients showed partial response to TKI therapy.
The number of generations and the status of exon 2 could affect age of onset of VHL-related manifestations. Onset age was an independent risk factor for overall survival. TKI therapy was effective in VHL patients with LDs. Our findings would further support clinical surveillance and decision-making processes.
约 20%-40%的常染色体显性遗传疾病 von Hippel-Lindau(VHL)病患者存在大片段缺失(LDs)。此类人群的研究较少。因此,我们旨在阐明 VHL 病患者 LDs 的基因型-表型相关性和临床结局。
在这项回顾性研究中,我们纳入了 50 个无关家系的 119 例 VHL 病患者,使用传统和下一代测序方法检测 LDs。其他种系突变通过 Sanger 测序确认。使用 Kaplan-Meier 和 Cox 回归分析不同组别的基因型-表型相关性和生存情况。我们还评估了酪氨酸激酶抑制剂(TKI)治疗的疗效。
<60 岁患者的总外显率为 95.2%。2 例 LDs 患者还携带 和 种系突变。视网膜血管母细胞瘤的发病年龄较早。存在 外显子 2 缺失的患者肾癌和胰腺病变的发病年龄更早。携带 LDs 和 缺失的 VHL 病患者发生肾癌的风险较低。发病年龄较早的患者预后较差。8 例患者中有 4 例(50%)对 TKI 治疗有部分反应。
代际数和外显子 2 的状态可能影响 VHL 相关表现的发病年龄。发病年龄是总生存的独立危险因素。TKI 治疗对 LDs 的 VHL 病患者有效。我们的发现将进一步支持临床监测和决策过程。